XXXX : why and how should we make the diagnosis?

@entity1 @entity66 @entity4404 @entity49 @entity1701 @entity3633 @entity715 @entity792
@entity1701 ( @entity1701 ) is characterized by recurrent @entity715 and/or pregnancy loss associated with persistently elevated levels of autoantibodies to phospholipids or plasma proteins. @entity1701 occurs both as a @entity66 and as a condition secondary to lupus and other @entity792 . Awareness of the polymorphic presentations of @entity1701 is vital given the risk of life-threatening @entity715 associated with this condition. Anticoagulant therapy is effective in preventing recurrent @entity715 . New biological markers have been developed, including autoantibodies to beta-2-glycoprotein 1 (anti-beta2GP1), @entity3633 (PE), and @entity4404 . These autoantibodies are not listed in the new diagnostic criteria set (Sapporo, 1999) because their usefulness needs to be validated and their detection standardized. Nevertheless, they may be helpful as part of a biological evaluation strategy for @entity1701 . Progress can be expected in the near future, particularly regarding prediction of @entity715 . Although no marker predicts @entity715 with complete certainty, persistent high titers of the IgG variants of one or more antiphospholipid antibodies (particularly circulating anticoagulant and anti-beta2GP1) indicate a high risk of @entity715 . Evaluation of other thrombogenic factors such as inherited @entity49 is probably useful in @entity1 with @entity1701 . Improvements in our ability to predict the risk of @entity715 may lead to novel strategies for prevention and treatment. New drugs such as complement factor (C3) inhibitors are being developed.
